Searching for the best place to inject Trulicity for weight loss? Here's what the evidence actually says

You've read about Trulicity helping people lose weight, here's the full picture

It's a reasonable trail to follow. Dulaglutide, like semaglutide and tirzepatide, belongs to the GLP-1 receptor agonist class. These medicines slow gastric emptying and reduce appetite, so it's understandable that weight loss appears as a side effect in people taking Trulicity for diabetes. The misconception worth setting down gently here is that this makes Trulicity a weight-loss medicine: the UK licence simply doesn't cover that indication, and a prescriber cannot lawfully prescribe it for weight management as a primary goal.

In clinical studies of dulaglutide in people with type 2 diabetes, modest weight changes were observed alongside glycaemic improvements. That's a different population, a different endpoint, and a different regulatory context from the dedicated weight-management trials that earned Mounjaro and Wegovy their UK licences. If weight loss is your goal, the detail on Trulicity and weight loss covers this distinction thoroughly.

The practical upshot: if you're already prescribed Trulicity for diabetes and want to understand the technique, your prescriber or diabetes nurse is the right person to walk through it. If you're looking for a licensed route to GLP-1 treatment for weight management, the starting point is a consultation with a prescriber who can assess the medicines that carry that licence.

Where GLP-1 injections actually go, and why site rotation matters

For subcutaneous GLP-1 injections in general, the three standard sites are the abdomen (avoiding a two-inch radius around the navel), the outer thigh and the upper arm. Rotating between them (and moving to a different spot within the same area each week) matters because repeated injections at a single point can cause lipohypertrophy: a localised thickening of fatty tissue that slows absorption unpredictably. Most people find the abdomen easiest to reach themselves; the upper arm typically needs a second pair of hands or a firm surface to stabilise.

Absorption is marginally faster from the abdomen than the thigh in general pharmacokinetic research, but for once-weekly medicines the clinical significance of that difference is small: the slow-release profile of a weekly injection smooths out site-to-site variation. What matters more in practice is consistency of technique, injecting at the right depth (subcutaneous, not intramuscular), changing the needle with each use, and allowing alcohol swabs to dry fully before injecting to avoid stinging. If you use fresh needles every time, a stock of compatible needles is worth keeping to hand.

The broader guide to injection site choice for weight-loss medicines covers technique and rotation in more depth, including how site choice interacts with clothing and lifestyle.

Which licensed weight-loss injections a UK prescriber can assess you for

Two injectable medicines hold a UK licence for weight management in adults. Mounjaro (tirzepatide), made by Eli Lilly, is a dual GIP and GLP-1 receptor agonist, the only one of its kind currently licensed in the UK for this purpose. In the SURMOUNT-1 trial, participants on the highest dose achieved an average body-weight reduction of around 20–21% over 72 weeks, as reported in the New England Journal of Medicine. Wegovy (semaglutide 2.4mg), made by Novo Nordisk, is a GLP-1 agonist; the STEP 1 trial reported an average reduction of around 15% over 68 weeks at the 2.4mg maintenance dose.

Both are prescription-only medicines. A prescriber considers your BMI, any weight-related health conditions, your other medicines and your medical history before recommending one over the other, or recommending neither if the clinical picture doesn't support treatment. If you're weighing up the options, the overview of UK weight-loss injections sets out how they compare.

The options for accessing weight-loss injections in the UK include NHS routes (with phased eligibility criteria) and regulated private services. For private prescriptions, the NHS tirzepatide patient information page on the NHS medicines section is a useful starting point for reading about the medicine before a consultation. Side effects reported in clinical trials were predominantly gastrointestinal (nausea, loose stools, reduced appetite) most noticeable after starting or a dose increase, and generally settling within a couple of weeks.

What a clinical assessment covers, and how to get started

A legitimate prescription for a weight-management injection follows a clinical assessment: your BMI, existing conditions, current medicines and broader health picture all feed into whether treatment is appropriate and, if so, which medicine fits. No regulated prescriber issues a weight-loss prescription based on a request alone, and finding a reputable online service means looking for one registered with the GPhC, verifiable at the GPhC pharmacy register.

At nume, every consultation is read and decided by a GPhC-registered Independent Prescriber, a real clinician, same day. Identity and current weight are verified before any prescription is issued. If treatment is clinically appropriate, medicines are dispensed from our own GPhC-registered pharmacy and delivered by DPD the next working day in plain, unbranded packaging. Our clinical team is there for aftercare seven days a week.

If you're ready to find out whether a licensed weight-loss injection is suitable for you, the next step is a free consultation. The weight-loss treatment overview explains what to expect before you begin.